Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Pharmaceuticals Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 14, 2022 to Discuss Your Rights - AUPH

Newsfile April 22, 2022

Investor Action Alert: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 22, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aurinia Pharmaceuticals Inc., of Class Action Lawsuit and Upcoming Deadline - AUPH

Newsfile April 21, 2022

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

PR Newswire April 21, 2022

Bronstein, Gewirtz & Grossman, LLC Notifies Aurinia Pharmaceuticals Inc. (AUPH) Investors of Class Action and Encourages Investors to Contact the Firm

Business Wire April 21, 2022

Shareholder Action Reminder: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 21, 2022

AUPH LAWSUIT ALERT: Levi & Korsinsky Notifies Aurinia Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire April 21, 2022

Shareholder Update: Contact Robbins LLP to Learn More About the Class Action Against Aurinia Pharmaceuticals Inc. (AUPH)

Business Wire April 20, 2022

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

Newsfile April 20, 2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aurinia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 14, 2022 - (NASDAQ: AUPH)

PR Newswire April 20, 2022

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Business Wire April 19, 2022

Bronstein, Gewirtz & Grossman, LLC Notifies Aurinia Pharmaceuticals Inc. (AUPH) Investors of Class Action and Encourages Investors to Contact the Firm

PR Newswire April 19, 2022

Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis

Business Wire April 19, 2022

Aurinia Pharmaceuticals Inc. Class Action: Levi & Korsinsky Reminds Aurinia Pharmaceuticals Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 14, 2022 - AUPH

Newsfile April 19, 2022

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Aurinia Pharmaceuticals Inc. (AUPH)

Business Wire April 19, 2022

ALERT: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AUPH

PR Newswire April 18, 2022

EQUITY ALERT: Rosen Law Firm Encourages Aurinia Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

Business Wire April 18, 2022

SHAREHOLDER ALERT: Holzer & Holzer Announces a Class Action Was Filed on Behalf of Aurinia Pharmaceuticals Investors (AUPH) and Encourages Investors With Significant Losses To Contact the Firm

Newsfile April 18, 2022

AURINIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Business Wire April 15, 2022

AUPH INVESTOR ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPH

Business Wire April 5, 2022